Two Sigma Securities LLC Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Two Sigma Securities LLC acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,505 shares of the company's stock, valued at approximately $212,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at $38,000. Covestor Ltd grew its position in shares of Protagonist Therapeutics by 5,200.0% during the fourth quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after buying an additional 1,612 shares in the last quarter. KBC Group NV lifted its position in shares of Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Protagonist Therapeutics by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock worth $121,000 after buying an additional 295 shares during the period. Finally, Cibc World Markets Corp purchased a new position in Protagonist Therapeutics in the fourth quarter worth $211,000. Hedge funds and other institutional investors own 98.63% of the company's stock.

Insider Activity at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total value of $1,700,850.36. Following the sale, the insider now owns 83,892 shares of the company's stock, valued at approximately $4,676,140.08. This trade represents a 26.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total transaction of $204,606.62. Following the transaction, the chief executive officer now directly owns 540,260 shares in the company, valued at $20,627,126.80. This trade represents a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,532 shares of company stock worth $3,665,786 over the last quarter. Company insiders own 5.40% of the company's stock.

Protagonist Therapeutics Trading Down 2.9 %

Protagonist Therapeutics stock traded down $1.30 during trading on Tuesday, hitting $42.98. 77,067 shares of the company were exchanged, compared to its average volume of 859,848. The business's 50 day moving average is $46.53 and its 200 day moving average is $42.77. The company has a market capitalization of $2.66 billion, a P/E ratio of 16.17 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 52 week low of $25.23 and a 52 week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of ($0.09) by $2.07. The firm had revenue of $170.64 million for the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. Equities analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PTGX. Wedbush reissued an "outperform" rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a research note on Friday, March 28th. The Goldman Sachs Group dropped their price objective on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, February 24th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. BTIG Research set a $73.00 price target on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. Finally, BMO Capital Markets raised their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $65.44.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.